Relmada Therapeutics Inc (NASDAQ: RLMD): Is Its Value Too High Compared To Others?

Relmada Therapeutics Inc (NASDAQ:RLMD) shares, rose in value on Thursday, April 16, with the stock price down by -0.75% to the previous day’s close as strong demand from buyers drove the stock to $0.29.

Actively observing the price movement in the last trading, the stock closed the session at $0.29, falling within a range of $0.2858 and $0.312. The value of beta (5-year monthly) was 0.409. Referring to stock’s 52-week performance, its high was $4.72, and the low was $0.24. On the whole, RLMD has fluctuated by -3.43% over the past month.

With the market capitalization of Relmada Therapeutics Inc currently standing at about $9.62 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-26.

Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RLMD’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the price of RLMD currently trading nearly 0.66% and -0.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.15, while the 7-day volatility ratio is showing 10.91% which for the 30-day chart, stands at 10.42%. Furthermore, Relmada Therapeutics Inc (RLMD)’s beta value is 0.15, and its average true range (ATR) is 0.03.

A comparison of Relmada Therapeutics Inc (RLMD) with its peers suggests the former has fared considerably weaker in the market. RLMD showed an intraday change of -0.75% in last session, and over the past year, it shrunk by -93.64%%.

Data on historical trading for Relmada Therapeutics Inc (NASDAQ:RLMD) indicates that the trading volumes over the past 10 days have averaged 0.28 and over the past 3 months, they’ve averaged 909.64K. According to company’s latest data on outstanding shares, there are 30.17 million shares outstanding.

Nearly 16.22% of Relmada Therapeutics Inc’s shares belong to company insiders and institutional investors own 25.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.62 million shares as on 2025-03-31, resulting in a short ratio of 4.07. According to the data, the short interest in Relmada Therapeutics Inc (RLMD) stood at 496.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.26 million. The stock has fallen by -44.27% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RLMD stock heading into the next quarter.

Most Popular